Thread by @BullsforBears

#glandpharma
#Q3marketupdates #Q3investorpresentations
Good show inr in mn
Rev 8945 /6712
PAT 2041 /1540
EPS 12.83 /9.95

9 months fy21 /20
Rev 26626 /20909
PAT 7365 /5780
EPS 47.12 / 37.31

Mkt wise
US 6021 /4853
India 1495 /1193
ROW 1078/413

R&D expenses INR Mn
Q3 fy21 434
Q3fy20 312
9M Fy21 916
9m Fy20 749

Net worth INR Mn
Mar 20 36462
Dec 20 56221

Net cash INR Mn
Mar 20 13202
Dec 20 28128

Capital expenditure
9M Fy20 1342
9M Fy21 1826

CFO
9M Fy20 4244
9M fy21 4056

New launches
9months fy21 - 31 product SKUs (4 mols)
US mkt - Dec 20 ,with partners filed 282 ANDAs, 226 approved, 56 pending

Core mkts (US,EU,Canada,Australia)
9M fy21 17415 mn
Growth 20%
Q3 fy21 6021 mn
Growth 24%

Domestic MKT
9M fy2110 product SKUs
Started Remdesivir mftg

Domestic mkt
9M fy21 4317 mn
Growth 20% yoy
Q3 fy21 1495 mn
Growth 25% yoy

Commissioned new pre filled syringe line at Pashamylaram facility

To enter vaccine mfg with annual capacity 40 mn vials

To enter new delivery systems- Pens & cartridges

Export to 60 countries

Centralized R&D lab with 265 personnel

7 facilities
4 finished dosage facilities - 767mn units
3 API facilities - 11000 kg/year
3API facilities provide in house mftg capabilities for critical APIs

No USFDA warning letter since inception, cGMP compliant at all facilities

35+ audits per year on avg

Diversified B2B led model across regulated mkts complemented by B2C model in India

Extensive portfolio - sterile injs, oncology ,opthal, complex injcs, NCE-1s, F2F ,505(2) Filings

1478 product registrations globally

Global generic injs mkt estimated $131 bn
$61.3 bn inj brand sales to lose patent protection 2020-24

Growth driver for injs - rising chronic diseases, convenience of new drug delivery systems, drug shortages in US

Barriers in inj mkt -
High capital reqs,stringent STDs,regltn

40% overall drug shortages betn 2014-18 in US were in injs

23 production lines with flexibility to accommodate diff product reqs
Dundigal - sterile injs,API
Pashamylaram - sterile injs ,penems
Vishakapatnam - oncology ,2 APIs

R&D expenditure as % of rev
Fy18 3.8
Fy20 3.5

Expertise in complex drug mols - LMWH ,Steroids ,Cytotoxics
Expanding capacity - Peptides ,Long acting injs, Suspensions, Hormones ,Pens ,Cartridges

New product contribution to revenue
2018 22%
2019 13
2020 9%

Promoted by Shanghai Fosun pharma ,global player listed on HKSE

Fosun is global pharma major,established player in China & Africa ,both key mkts for injs
Benefit from Fosun to expand in China

Unroll
@threadreaderapp
Compile
@threader_app

#pharma #cdmo #API #nifty #stocks

@tycoonmindset05 @nid_rockz @thescorpionphil @AdityaKhemka5